SCHEMBL294408

SCHEMBL294408

Cc1cc2ccccc2c([O])c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.48
CYP2A6 P11509 3/20 0.48
TSHR P16473 2/20 0.45
ALDH1A1 P00352 6/20 0.43
HSD17B10 Q99714 4/20 0.42
HPGD P15428 4/20 0.42
KDM4E B2RXH2 3/20 0.42
GAA P10253 2/20 0.42
BRD4 O60885 1/20 0.42
TYMP P19971 1/20 0.40
HIF1A Q16665 2/20 0.39
CYP1B1 Q16678 1/20 0.39
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
GLA P06280 1/20 0.38
CYP2C19 P33261 1/20 0.38
CCR1 P32246 1/20 0.37
CCR8 P51685 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8376482 0.83 BRD4 (0.40) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL459684 0.79 CYP1A2 (0.56) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
Ammonia Solution, Strong SCHEMBL4639022 0.77 CYP1A2 (0.54) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL10630656 0.77 CYP1A2 (0.54) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL10630661 0.77 CYP1A2 (0.54) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL31001028 0.77 CYP1A2 (0.52) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL28848790 0.77 CYP1A2 (0.54) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
SCHEMBL7305557 0.77 CYP1A2 (0.45) CYP1A2CYP2A6ALDH1A1HSD17B10HPGD
SCHEMBL82369 0.76 ALDH1A1 (0.52) CYP1A2CYP2A6TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL5928867 0.76 CYP1A2 (0.52) CYP1A2CYP2A6TSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745372-B2 Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2020-08-18 US claimed
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP claimed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP claimed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US claimed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO claimed
US-20240125678-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) 2024-04-18 US disclosed
WO-2024053316-A1 COMPOUND, EXTRACELLULAR VESICLE STAINING AGENT, AND FLUORESCENT STAINING METHOD FOR EXTRACELLULAR VESICLES 国立大学法人東海国立大学機構 2024-03-14 WO disclosed
EP-4286388-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES National University Corporation Tokai National Higher Education and Research System (JP) 2023-12-06 EP disclosed
EP-3275527-B1 GAS-PERMEABLE MEMBRANE, USE OF A COMPOSITION FOR FORMING SUCH MEMBRANE AND PROCESS FOR PRODUCING IT NANOMEMBRANE TECH INC (JP) 2023-10-11 EP disclosed
CN-116745272-A Compound, cell vesicle staining agent, and method for fluorescent staining of cell vesicles 国立大学法人东海国立大学机构 2023-09-12 CN disclosed
US-10751672-B2 Gas-permeable membrane NanoMembrane Technologies, Inc. (JP) 2020-08-25 US disclosed
US-10745372-B2 Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2020-08-18 US disclosed
EP-1919907-A2 HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-14 EP disclosed
EP-1847545-A1 SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME Ube Industries, Ltd. (JP) 2007-10-24 EP disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP disclosed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US disclosed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO disclosed
US-5629406-A AMINO ACID DERIVATIVES SANKYO COMPANY, LIMITED (JP) 1997-05-13 US disclosed
EP-0587311-A1 Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1994-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240125678-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES EXOSC4, EXOSC5, EXOSC9 CYP1A2 3942/4885CYP2A6 3903/4885TSHR 3500/4885
US-20050215526-A1 Melanin concentrating hormone receptor antagonist MCHR1, MC1R, NPY1R CYP1A2 402/4885CYP2A6 795/4885TSHR 17/4885
US-10745372-B2 Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method ASH2L, MLLT1, FRG1 CYP1A2 1815/4885CYP2A6 1906/4885TSHR 3984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.